Tatva Chintan Pharma Chem Ltd - 543321 - Communication To Shareholders - Dividend For FY 2022-23 - Intimation On Tax Deduction At Source (TDS) / Withholding Tax On Dividend
Communication to Shareholders - Dividend for FY 2022-23 - Intimation on Tax Deduction at source (TDS) / withholding tax on Dividend Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the earnings call held on 04 August 2023 post announcement of financial results of the Company for the quarter ended 30 June 2023 Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Monitoring Agency Report of the Company for the quarter ended 30 June 2023 Tatva Chintan Pharma Chem Ltd - 543321 - Statement Of Deviation / Variation In Utilization Of Funds Raised Through IPO
Statement of Deviation / Variation in Utilization of funds raised through IPO for the quarter ended 30 June 2023 Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Tatva Chintan Pharma Chem Limited has informed the Exchange about schedule of investors meeting that the Company would be participating on 11 August 2023, as annexed. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Tatva Chintan Pharma Chem Limited has informed the Exchange about schedule of investors meetings that the Company would be participating on 09, 10 and 11 August 2023, as annexed. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of extract of Financial Results of the Company for the quarter ended 30 June 2023. Q1FY24 Quarterly Result Announced for Tatva Chintan Pharma Chem Ltd.
Specialty Chemicals company Tatva Chintan Pharma Chem announced Q1FY24 results: Revenue from operations of Rs 1,143.64 million in Q1FY24 compared to Rs 884.02 million in Q1FY23, up 29.37% YoY EBITDA (Excl. other income) of Rs 213.43 million in Q1FY24 compared to Rs 152.17 million in Q1FY23, up 40.26% YoY EBITDA Margin of 18.66% in Q1FY24 compared to 17.21% in Q1FY23 Profit before tax of Rs 134.20 million in Q1FY24 compared to Rs 136.95 million in Q1FY23, down 2.01% YoY Profit after tax of Rs 95.04 million in Q1FY24 compared to Rs 97.97 million in Q1FY23, down 2.99% YoY PAT margin of 8.31% in Q1FY24 compared to 11.08% in Q1FY23 Cash profit of Rs 155.16 million in Q1FY24 compared to Rs 121.3 million in Q1FY23, up 27.91% YoY Commenting on the results, Chintan Shah, Managing Director said, "I am pleased to inform you that TATVA CHINTAN has begun this financial year on a satisfactory note, in line with our expectations and we expect the improvement to gradually continue over the coming quarters. The year has started with better off-take and a favorable product mix translating into better numbers for this quarter. During this quarter, the company has reported revenue from operations of Rs 1,144 million, a growth of 29% YoY from Rs 884 million. EBITDA during the quarter was at Rs 213 million, a growth of 40% YoY from Rs 152 million. EBIDTA margins were at 18.7% v/s 17.2% in Q1FY23. The inventory (other than spares and packing materials) at consolidated levels has come down by nearly Rs 125 million from Rs 1,325 million as of March 2023 to Rs 1,200 million as of June 2023. The logistic costs have steadily reduced to realistic levels which has come as a breather. Also, the price reduction in the chemical space seems to have lost pace and the prices have begun to stabilize in the past few weeks. I am quite happy and proud, to inform you that we successfully commenced commercial production from the newly expanded facility at Dahej SEZ. With this the installed reactor capacity increased to 500KL from 294KL and assembly lines increased from 27 to 39." Result PDF Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Financial Results of the Company for the quarter ended 30 June 2023